NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Ltd. Kck sold 5,270,845 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
NeuroPace Stock Down 3.2 %
NASDAQ:NPCE traded down $0.46 during midday trading on Friday, reaching $13.77. The company had a trading volume of 532,543 shares, compared to its average volume of 242,007. The firm has a market capitalization of $411.03 million, a price-to-earnings ratio of -13.77 and a beta of 2.05. The stock's fifty day simple moving average is $12.49 and its 200-day simple moving average is $9.42. NeuroPace, Inc. has a 12-month low of $5.45 and a 12-month high of $17.45. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03.
Institutional Trading of NeuroPace
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Advisers LP acquired a new stake in NeuroPace in the fourth quarter valued at $117,000. Two Sigma Investments LP acquired a new stake in NeuroPace in the fourth quarter valued at $293,000. Point72 Asset Management L.P. acquired a new stake in NeuroPace in the fourth quarter valued at $369,000. Jacobs Levy Equity Management Inc. acquired a new stake in NeuroPace in the fourth quarter valued at $639,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in NeuroPace in the fourth quarter valued at $112,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research analysts have recently commented on the company. Wells Fargo & Company raised their price target on NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a research report on Thursday, January 30th. UBS Group started coverage on NeuroPace in a report on Tuesday, January 21st. They issued a "buy" rating and a $17.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their target price on NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $14.80.
Get Our Latest Research Report on NeuroPace
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Read More
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
